Onconetix (ONCO) Free Cash Flow (2021 - 2026)
Onconetix (ONCO) posted quarterly Free Cash Flow of -$2.1 million for Q1 2026, down 5.02% year-over-year from -$2.2 million in Q1 2025, and up 32.26% quarter-over-quarter from -$3.1 million in Q4 2025.
Onconetix (ONCO) Free Cash Flow (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Free Cash Flow for 6 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 5.02% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$9.8 million (down 34.48% YoY), while the FY2025 annual figure was -$9.7 million, up 7.83% from the prior year.
- Free Cash Flow advanced to -$2.1 million in Q1 2026 per ONCO's latest filing, from -$3.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $9.3 million in Q4 2023 and bottomed at -$9.1 million in Q3 2023.
- Historically, Free Cash Flow has averaged -$2.2 million across 5 years, with a median of -$2.1 million in 2026.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 730.38% — and 2023, when it jumped 430.11%.
- Onconetix's Free Cash Flow stood at -$2.8 million in 2022, then surged by 430.11% to $9.3 million in 2023, then plunged by 109.87% to -$921521.0 in 2024, then slumped by 236.4% to -$3.1 million in 2025, then surged by 32.26% to -$2.1 million in 2026.
- Business Quant data shows ONCO's Free Cash Flow at -$2.1 million in Q1 2026, -$3.1 million in Q4 2025, and -$3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -1.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.92 Mn |
| Jun 30, 2026 | -1.92 Mn |
| Mar 31, 2026 | -2.10 Mn |
| Mar 31, 2026 | -2.10 Mn |
| Dec 31, 2025 | -3.10 Mn |
| Dec 31, 2025 | -3.10 Mn |
| Sep 30, 2025 | -3.19 Mn |
| Sep 30, 2025 | -3.19 Mn |
| Jun 30, 2025 | -1.41 Mn |
| Jun 30, 2025 | -1.41 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Dec 31, 2024 | -921,521.00 |
| Dec 31, 2024 | -921,521.00 |
| Sep 30, 2024 | -1.15 Mn |
| Sep 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -3.22 Mn |
| Jun 30, 2024 | -3.22 Mn |
| Mar 31, 2024 | -5.24 Mn |
| Mar 31, 2024 | -5.24 Mn |